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Abstract: Background: Depression and anxiety are common mental health concerns worldwide.
Broad-spectrum multi-vitamin/mineral approaches have been found to alleviate a number of
psychiatric symptoms. We investigated the effects of a nutrient intervention program, which
includes optimizing vitamin D levels, on depression and anxiety outcomes from community-based
program. Methods: We evaluated self-reported health measures of depression and anxiety
collected as part of a community-based program focused on optimizing overall health through
nutritional supplementation, education and lifestyle advice. Results: Data were collected from
16,020 participants, with measures including European Quality of Life Five Dimensions (EQ-5D)
and Targeted Symptoms List (TSL) providing self-reported depression and anxiety. More than 56%
of participants were identified as having elevated levels of depression and anxiety at baseline as
reported on the EQ-5D. After one year in the program, 49.2% (n = 7878) of participants who reported
any level of depression or anxiety at baseline reported improvement at follow-up. Of those who
reported severe/extreme depression at baseline (n = 829), 97.2% reported improvement after one year.
Regression analyses revealed a significant association of improvement in depression and anxiety with
higher vitamin D status (>100 nmol/L) and more strenuous physical activity. Conclusion: Overall,
people from the general population who suffer from mood and anxiety problems may benefit from
improved nutritional status achieved with nutritional supplements.
Keywords: depression; anxiety; vitamin D; nutritional supplements; multivitamin/multimineral;
mental health
1. Introduction
The World Health Organization estimates that 350 million people worldwide are affected by
depression and anxiety. The Global Burden of Disease Study in 2010 identified depressive disorders as
a leading cause of burden and responsible for 3.8% of global Disability Adjusted Life Years (DALY) [1].
As a contributor to DALY, depression is expected to be the second highest concern for all ages by
2020 [2]. In Canada, it is estimated that over 6.7 million people live with a mental health problem
(in comparison with 3.5 million with type 2 diabetes mellitus) [3]. Economic costs of mental health
problems are estimated to be at least $50 billion per year [3]. With current medications purported to
only have a modest benefit [4], few new psychiatric drugs on the horizon, and some studies suggesting
medication can do more harm than good [5–8], there are calls to revisit the impact that nutrition can
have on mental health [4,9].
Biologically, nutrition is interconnected with depression through hormonal, neurotransmitter
and signalling pathways in the gut that modulate brain functions such as appetite, sleep, reward
Nutrients 2018, 10, 152; doi:10.3390/nu10020152 www.mdpi.com/journal/nutrients
Nutrients 2018, 10, 152 2 of 17
mechanisms, cognitive function and mood [10]. All biochemical pathways require vitamins and
minerals as co-factors for proper enzyme function and insufficient nutrient levels can negatively
impact a wide range of metabolic processes. There are a number of different nutrients involved in
pathways relevant to mental disorders and brain function [11].
Many nutrients have been investigated individually, including: B vitamins, vitamin D, choline,
iron, zinc, magnesium, S-adenosyl methionine, amino acids such as taurine and probiotics. For the
most part, studies of single nutrient treatments for mood disorders such as vitamin D report only
modest symptom improvement or null results [12]. The evidence for B vitamins is stronger, such that a
systematic review reported sufficient evidence to support the use of combination high dose B vitamins
in the treatment of stress and anxiety in the general population [13]. Overall, no single nutrient
stands out as a treatment for mental health problems. However, a broad-spectrum multivitamin and
multimineral approach may alleviate symptoms in a number of psychiatric ailments.
Nutrition and dietary patterns have been linked with depression onset, and the maintenance and
severity of symptoms [14–17]. Furthermore, several trials have demonstrated improvements in not only
depression, but anxiety and stress response through supplementation with multivitamin/multimineral
formulas and B complex vitamins [18–23]. In fact, the International Society for Nutritional Psychiatry
Research has issued a consensus statement that “nutrition and nutraceuticals should now be considered
as mainstream elements of psychiatric practice, with research, education, policy and health promotion
reflecting this new paradigm [24]”. A full range of vitamins and minerals are obligatory cofactors
involved in the production of neurotransmitters. For example, in the production of serotonin, the major
neurotransmitter involved in depressive disorders, there are requirements for vitamin B6, vitamin D,
iron, copper and molybdenum.
A multivitamin/mineral (MVM), in which many ingredients were given at levels higher than
recommended dietary allowance (RDA) but generally lower than the upper level (UL), has been shown
to improve depressive symptoms in bipolar individuals [25–29]. A MVM was also found to significantly
reduce stress and anxiety following a series of earthquakes and a flood [22,29–31]. Despite enrolling
participants who were not clinically depressed, two clinical trials have found that micronutrient
supplementation improved symptoms of depression [32,33]. Collectively, the evidence suggests that
a spectrum of nutrients may be effective for reducing and preventing depression, stress and anxiety.
We hypothesized that optimal nutrient status, as measured by serum 25-hydroxyvitamin D (25(OH)D)
levels above 100 nmol/L [34] and serum vitamin B12 above 450 pmol/L [35], would have a protective
effect against depression and anxiety and that supplementation to achieve “optimal” nutrient status
would improve depression and anxiety.
In the present study, we characterize the prevalence and severity of symptoms of depression
and anxiety in participants in a community-based prevention program, before and after one year
of exposure to nutritional supplements (a combination of vitamin D3, MVM and other nutrients),
to determine if there was a benefit of supplementation with a broad spectrum of nutrients in a
comparison sample. We further investigated the impact of supplementation in a subgroup of
participants who self-reported extreme or severe depression and anxiety at entry to the program.
2. Materials and Methods
2.1. Intervention
The Pure North S’Energy Foundation (Pure North) is a not-for-profit wellness program focused
on the prevention of chronic diseases including mental illness, type 2 diabetes mellitus, cardiovascular
disease and cancer. The Pure North program offers lifestyle advice, education and nutritional
supplements to its participants. Dietary advice typically includes aspects of the DASH diet developed
to lower blood pressure without medication when appropriate for physical health outcomes, proper
food portion education, encouraging plenty of fruit and vegetables (5–10 servings/day) and foods
rich in omega-3 fatty acids, restriction of added sugar to less than 25 g/day and sodium to less than
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2300 mg/day. Other lifestyle advice consists of proper sleep hygiene, smoking cessation, at least
150 min of physical activity each week and moderate alcohol consumption.
Supplement recommendations are based on analysis of each participant’s biometric measurements
(including BMI), blood results and clinical intake data. Health care professionals review and explain
blood work results with the participant and, based on their clinical knowledge and nutrient expertise,
make recommendations accordingly. Each participant is treated as an individual and a treatment
plan developed to meet that individual’s nutrient requirements. All participants are encouraged to
achieve a 25(OH)D level of at least 100 nmol/L and vitamin D dosages were adjusted accordingly for
the individual.
The core supplements provided to everyone are in daily packets, Vitality Packs, and contain:
the multivitamin and multimineral formula (Vital 2 Platinum; Table S1), Omega-3 fatty acids
(400 mg EPA and 200 mg DHA), Vitamin C (1000 mg), Vitamin B12 (5000 µg methylcobalamin),
Probiotics (Biffidobacterium and Lactobacillus strains, 10 billion CFU) and Vitamin D3 drops. Vitamin D3
supplementation is individualized to target an optimal serum 25-hydroxyvitmainD (25(OH)D)
concentration, above 100 nmol/L [36]. Doses of vitamin D3 are often in excess of the UL (4000 IU/d)
and given under medical supervision [37]. Further supplements in addition to the Vitality Packs may
be recommended based on individual requirements.
2.2. Assessments
Participants in the Pure North program are assessed at each visit to the clinic. Visits typically
occur every 6–12 months to monitor lifestyle modification or disease condition change, and to adjust
supplement doses if required. Any participant with obvious clinical depression or anxiety who requires
closer monitoring or psychiatric medications is referred to their family physician. Assessments include
biometrics (including blood pressure, height, weight, BMI, etc.), clinical intake (including medical
history (such as pernicious anemia and H. pylori infections that might affect vitamin B12 absorption),
current medications (including acid blockers and proton pump inhibitors that might affect vitamin
B12 absorption), complaints and health goals), blood work (a number of biomarkers are measured
including serum 25(OH)D, vitamin B12, arachidonic acid (AA) and eicosapentaenoic acid (EPA)),
and completion of a questionnaire (including demographic data and self-reported health assessments).
All blood sample preparation and biochemical measurements were performed by Doctor’s Data
Laboratory (St. Charles, IL, USA), a fully accredited laboratory. Serum 25(OH)D was measured using
Liquid Chromatography and tandem Mass Spectrometry (LC/MS-MS) with the inter-assay CV of 2.4%.
Serum vitamin B12 was measured on an automated analyser with a chemiluminescent immunoassay
(Beckman Coulter) with a CV of 7.7%. AA and EPA were measured using gas chromatography.
For the present study, we utilized serum 25(OH)D and vitamin B12 concentrations, available
measures of nutrient status. Low levels of vitamin D have previously been linked to mental health
disorders, including mood disorders such as depression [38–40]. Vitamin D is of particular interest due
to its various roles in the brain and in neurotransmitter synthesis [41] and the heightened prevalence
of vitamin D deficiency (serum 25(OH)D <50 nmol/L) and mood disorders in Canada (more than
32% and nearly 13%, respectively) [42,43]. B vitamins are important for adrenal support, energy
production and neurotransmitter synthesis [44] and vitamin B12 deficiency (<148 pmol/L) is common
worldwide [45]. Serum vitamin B12 is a measurable indicator of B12 status. Unfortunately, we are not
easily and reliably able to measure the status of all nutrients in the body.
2.3. Self-Reported Depression and Anxiety
The European Quality of Life Five Dimensions (EQ-5D) assessment is a standardised instrument
used to measure health status in a wide range of health conditions and treatments. The EQ-5D
is a widely used questionnaire for calculating quality-adjusted life years (QALYs) for assessing
cost-effectiveness in healthcare. Participants complete the EQ-5D at each visit to the clinic. The EQ-5D
reflects the impact of common mental health conditions, such as mild to moderate depression and
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anxiety, on daily function [36] and has been found to be sensitive enough to pick up improvements
associated with treatment in patients with depression [46]. We utilized the EQ-5D to investigate
self-reported depression and anxiety in a community sample.
In addition to the EQ-5D participants completed the Targeted Symptoms List (TSL)—a wellbeing
assessment tool developed in-house. The TSL assesses 16 mental and physical health outcomes on a
scale of 1–10 (1 = never through to 10 = always) with a focus on common health complaints including:
anger, anxiety, confusion, coordination problems, depression, fatigue, headache, joint pain, loss of
sense (smell/taste), memory loss, moodiness, muscle weakness, numbness in arms/legs, shakiness of
hands, stomach problems (digestive), and unintentionally dropping things. In addition, the TSL mental
health score (MHS) is a composite score of depression, anxiety, and moodiness. For the purposes of
the present study, we have focused on 3 TSL scores: depression, anxiety and the calculated MHS.
Depression and anxiety were measured via self-report in the population at baseline, the time of
their first interaction with the Pure North program with a closer look at participants who reported
severe or extreme depression/anxiety on the EQ-5D. We further utilized blood markers of nutritional
status, 25(OH)D and vitamin B12, to investigate whether the effects of the nutrition-based intervention
on levels of reported depression, anxiety and MHS were associated with changes in these nutrients
over time.
This study was an analysis conducted utilizing a database of participant information collected as
part of a community program (secondary use of data). The protocol of current database analysis was
approved by the Research Ethics Board at St. Mary’s University in Calgary, Alberta (File# 073FA2017).
Informed consent was obtained from all individual participants included in the study to use their
information to evaluate the program.
2.4. Statistical Analyses
Statistical analyses were completed using SPSS v23 (SPSS Inc., Chicago, IL, USA). Descriptive
statistics are presented as mean ± standard deviation. Intent-to-treat analyses were performed; as
such mean follow-up values were used for participants who had baseline measures but not follow-up
measures (mean imputation method). Since the data were not normally distributed, non-parametric
tests were applied. Wilcoxon Signed Rank Test (WSRT) was performed to evaluate changes in different
parameters over one-year. Mann–Whitney U-test and Kruskal–Wallis tests were utilized to compare
categorical groups of vitamin D and vitamin B12 status. Chi Square testing was performed to determine
the association between levels of anxiety and depression and 25(OH)D (>100 nmol/L) and B12 status
(>450 pmol/L). Binary Logistic Regression was performed to investigate the relationship between
25(OH)D and vitamin B12 with changes in mental health status over time. Body mass index (BMI),
age, gender, tobacco use, alcohol use, physical activity, fruit and vegetable consumption, fish and tuna
consumption, AA:EPA and inflammation (CRP ≥ 10 mg/L) were considered as cofactors in these
analyses. Significance was defined as p < 0.05. For determining effect size (ES), Cohen’s test was
conducted using STATA version 14. Cohen’s d was used to estimate effect sizes, with 0.2 indicating a
small effect, 0.5 a medium effect and 0.8 a large effect.
3. Results
3.1. Baseline Demographics
Data were collected for 16,020 participants (60% female) who entered the program and completed
an EQ-5D. The mean age was 54.2 ± 16.0 (range 18–95) years. Of these, 1971 (16%) self-reported mental
health problems or previous diagnoses of depression, anxiety, stress, Attention-Deficit/Hyperactivity
Disorder (ADHD), Post-Traumatic Stress Disorder (PTSD), Seasonal Affective Disorder (SAD), or other
mental health disorders. There were 2123 (20%) who reported taking medications used to treat
depression and anxiety, of which 45.0% reported both depression or anxiety and taking medication.
At program entry, serum 25(OH)D level was not significantly different between participants taking
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medication (77.8 ± 27 nmol/L) and those not (77.9 ± 27 nmol/L). There were 3875 participants who
reported hypertension, 1656 with diabetes, and 1642 cases of cancer (past or present). Vitality packs
were provided for 96% of participants and equivalent supplements provided to the remaining 4% who
did not take the vitality pack for various reasons (e.g., one of the supplements was deemed unnecessary
or did not agree with the participant). In addition, 44% of participants were recommended extra
nutrients based on individual need.
The body mass index (BMI) distribution was 35.0% normal (18.5–24.9), 35.7% overweight (25–29.9)
and 27.7% obese (>30), similar to the measured BMIs for the Canadian population reported by
Statistics Canada at 36.1%, 36.8% and 25.1%, respectively [47]. At program entry, 84.0% of participants
were considered to have suboptimal vitamin D levels (25(OH)D < 100 nmol/L) with 14.7% being
deficient (25(OH)D < 50 nmol/L). Suboptimal vitamin B12 levels, <450 pmol/L, were found in
75.5% of participants at baseline. Medical conditions that can influence vitamin B12 absorption were
investigated. In the four cases of pernicious anemia, serum vitamin B12 levels increased from 214 to
1159 pmol/L, similar to response found in the rest of the population. There were three cases with
H. pylori infection in whom serum vitamin B12 levels increased from 308 to 503 pmol/L. Twelve percent
of participants were taking acid blockers, such as proton pump inhibitors, with no significant difference
in serum vitamin B12 levels between participants taking (427 ± 1543 increased to 1049 ± 2662 pmol/L)
and those not taking (421 ± 1047 increased to 995 ± 1264 pmol/L) acid blockers.
More than half of participants (56.2%) reported some level of depression or anxiety at the entry
to the program (Table 1). Eighty-one per cent of participants who reported a history of depression or
anxiety and 87% who reported taking medications for depression and anxiety, reported low levels
of depression and anxiety at baseline (none to moderate). Five percent (5.2%) of the population
reported severe or extreme depression at program entry, with more than half of those having reported
a history of or taking medications for depression/anxiety (Table 1). After one year in the program,
there was no significant difference in serum 25(OH)D levels between participants taking anxiety or
depression-related medication (111 ± 31 nmol/L) and those not taking medications (112 ± 32 nmol/L).
There was no significant difference in the proportion of participants taking medications for anxiety or
depression (1.0%) in comparison with those not taking medications (1.3%).
Table 1. Baseline demographics and self-reported levels of anxiety and depression on European Quality
of Life Five Dimensions (EQ-5D).
Level of Anxiety or Depression
Reported on EQ-5D Total (%) Female (%)
% with Reported History of
Depression/Anxiety
% with Reported Medication
Use for Depression/Anxiety
None 7014 (43.8) 3951 (56.3) 231 (4.4) 418 (9.3)
Slight 5417 (33.8) 3451 (63.7) 598 (14.3) 702 (20.3)
Moderate 2763 (17.2) 1675 (60.6) 772 (34.0) 718 (38.8)
Severe 577 (3.6) 323 (56.0) 243 (49.5) 184 (46.5)
Extreme 249 (1.6) 156 (62.7) 127 (62.3) 101 (61.2)
Total 16,020 (100) 9556 (59.7) 1971 (16) 2123 (20.5)
The severity of depression/anxiety was also significantly correlated with several lifestyle
characteristics (Table S2). Participants who reported severe or extreme depression/anxiety at program
entry often consumed no fruit (p < 0.001), vegetables (p < 0.001), and fish (p = 0.03) or consumed fewer
servings relative to those who were not depressed/anxious. Participants who used tobacco (p < 0.001),
drank heavily (p < 0.001) and were less physically active (p < 0.001), were also likely to report severe
or extreme depression/anxiety at program entry. Serum 25(OH)D levels were significantly lower in
depressed/anxious participants who were less physically active (66.5 ± 28 nmol/L) compared to those
who were more physically active (76 ± 24 nmol/L).
Because of the often cited ceiling effect found with the EQ-5D [48–50], we utilized a second
measure of depression and anxiety from an in-house questionnaire, the TSL, which had been previously
validated against both the EQ-5D and the SF-12 Health Survey. Reported depression/anxiety on
the EQ-5D is compared with TSL scores in Table 2. The depression/anxiety aspect of the EQ-5D
followed similar distribution patterns as TSL scores. Reported depression/anxiety on the EQ-5D had a
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significant correlation with the TSL anxiety (r = 0.66, p < 0.001), depression (r = 0.67, p < 0.001) and
MHS (r = 0.71, p < 0.001). In addition, the TSL mental health score significantly correlated with the
SF-12’s Mental Component Summary (MCS-12) score in a subset of participants who completed both
(n = 2084, r = 0.68, p < 0.001; data not shown). These results support the use of the MHS to assess
mental wellbeing and to investigate nutrient effects on depression and anxiety in this population.
Table 2. Baseline Comparison of European Quality of Life Five Dimensions (EQ-5D-Rated) Level of




Depression Score * p-Value
Mean TSL
Anxiety Score * p-Value
Mean TSL Mental
Health Score * p-Value






Slight 4.00 ± 2.0 4.33 ± 2.0 3.98 ± 1.7
Moderate 5.84 ± 2.3 6.25 ± 2.2 5.68 ± 1.8
Severe 7.50 ± 2.3 7.69 ± 2.2 7.11 ± 1.8
Extreme 8.00 ± 2.6 8.31 ± 2.4 7.57 ± 2.2
* Kruskal–Wallis test (between levels comparison).
3.2. Comparison between Baseline and One-Year Follow-Up
All participants at baseline were included in this intent-to-treat analysis (n = 16,020). There were
4159 participants who returned for their follow-up in the clinic within 6–18 months after the initial
visit, average 12 months. A comparison of baseline measures between participants who persisted in
the program (returned for follow-up in the specified time frame) and those that did not, found that
Persisters were older, more were female, they had higher baseline 25(OH)D and vitamin B12 levels,
lower AA:EPA and reported less depression (mean 3.04 vs. 3.73 on TSL) and anxiety (mean 3.36 vs. 4.04
on TSL) (Table 3).
Table 3. Baseline comparison of Participants who stay in the program for one year (Persisters) to those
that had a baseline visit only (Drop-outs).
Variable Persisters (n = 4159) Drop-outs (n = 11,861) p Value
Age (years) 62.9 ± 11.9 51.1 ± 16.7 <0.001 *
% Female 63.4 58.3 <0.001 #
BMI 27.6 ± 5.5 27.5 ± 5.8 0.6
25(OH)D (nmol/L) 85 ± 31 73 ± 27 <0.001 *
Vitamin B12 (pmol/L) 454 ± 325 358 ± 286 <0.001 *
AA:EPA 13.6 ± 7.1 18.3 ± 7.7 <0.001 *

















TSL mental health score 3.04 ± 2.0 3.75 ± 2.2 <0.001 *
TSL anxiety 3.36 ± 2.3 4.04 ± 2.6 <0.001 *
TSL depression 3.04 ± 2.3 3.73 ± 2.6 <0.001 *
* p value < 0.05 (Mann–Whitney U-test), # p value < 0.05 (Chi square test).
After an average of one year, we examined levels of depression/anxiety reported on the
EQ-5D at follow-up. Overall, 46.8% of participants did not report any change in their level of
depression/anxiety, whereas 4.1% reported higher levels and 49.2% reported improvement (Table 4).
Of those who reported severe/extreme depression at baseline [n = 577 (severe), n = 249 (extreme)],
97.2% reported improvement, 2.4% reported no change and 0.4% were worse after one year in the
program (Chi-square, p < 0.05). For those who reported none/slight/moderate levels of depression or
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anxiety, 58.4% improved, 3.6% worsened and 38% did not report any change. Per protocol analyses
revealed similar results to ITT (data available upon request).
Table 4. Change in Reported Level of Depression and Anxiety at One Year.
Baseline Level of Depression/Anxiety
Change at One Year Number (%)
Worse Improve No Change Total
None 430 (6.1) 0 6584 (93.9) 7014
Slight 177 (3.3) 4569 (84.3) 671 (12.4) 5417
Moderate 40 (1.4) 2511 (90.9) 212 (7.7) 2763
Severe 4 (0.7) 552 (95.7) 21 (3.6) 577
Extreme 0 246 (98.8) 3 (1.2) 249
Total 651 (4.1) 7878 (49.2) 7491 (46.8) 16,020
Chi-Square p < 0.001
We validated the use of TSL scores as a numeric scale by comparing baseline TSL scores between
those who reported severe/extreme depression on the EQ-5D with those who reported none, slight or
moderate levels. As expected, those who reported severe/extreme depression/anxiety on the EQ-5D
had significantly higher mean TSL scores than the rest of the population for both depression (7.65 ± 2.4
vs. 3.4 ± 2.4, respectively) and anxiety (7.9 ± 2.3 vs. 3.7 ± 2.4, respectively). Effect sizes were used to
compare the magnitude of change between baseline and follow-up. Effect sizes were much larger for
those who started the nutrients in a severe/extreme depressed or anxious state (Table 5).
Table 5. Effect Sizes (ES) * for Targeted Symptoms List (TSL) Levels of Depression, Anxiety and Mental
Health Score.
TSL Score EQ-5D “Severe/Extreme” forDepression/Anxiety
EQ-5D “None/Slight/Moderate”
for Depression/Anxiety
ES for Depression 1.85 (1.71–1.99) 0.21 (0.18–0.23)
ES for Anxiety 1.94 (1.80–2.08) 0.22 (0.19–0.24)
ES for MHS 2.07 (1.93–2.22) 0.27 (0.24–0.30)
N 563 11,033
* Cohen’s d (with 95% confidence intervals) measure of effect sizes: 0.2 is small, 0.5 is medium, and 0.8 is large
MHS = Mental Health Score.
We examined the effect of the nutrient intervention program on changes in measured nutrients,
serum 25(OH)D, vitamin B12 and AA:EPA in relation to baseline depression/anxiety level. Similar
significant improvements in 25(OH)D, vitamin B12 and AA:EPA were found in both groups
(severe/extreme vs. none/slight/moderate), without any reported side effects (Table 6). Per protocol
analyses revealed similar results to ITT (data available upon request).
After one year in the program, more than 62% of participants had serum 25(OH)D levels above
100 nmol/L compared to 25% at baseline. Kimball et al. (2017) [37], assessing safety in the Pure
North population, previously showed that serum 25(OH)D levels up to 300 nmol/L were found to
be safe, without any evidence of toxicity. In the current study, following vitamin D supplementation
and a significant increase in serum 25(OH)D levels over time, no participant obtained a level above
300 nmol/L and there were no cases of vitamin D toxicity.
To investigate whether the improvements in depression and anxiety were related to the nutrient
supplementation program, we utilized serum 25(OH)D and vitamin B12 levels. We compared 25(OH)D
and vitamin B12 levels between those participants who reported being severe/extreme depressed or
anxious versus being none/slight/moderate depressed or anxious at baseline (Table 7). We compared
the magnitude of the changes between baseline and one year in participants considered deficient with
those who had reached optimal levels for vitamin D and B12 at follow-up, for both categories. Among
those who were severe/extreme anxious or depressed, moderate effect sizes, ranging from 0.5 to 0.6,
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were found in participants who remained below optimal vitamin B12 levels (<450 pmol/L) and serum
25(OH)D levels (<100 nmol/L). In contrast, those participants who achieved optimal vitamin B12 and
optimal 25(OH)D at follow up, experienced significant improvements in depression, anxiety and MHS
on TSL with effect sizes in the range of 1.95 to 2.33. In participants with optimal vitamin B12 and serum
25(OH)D at baseline, the effect sizes for depression/anxiety outcomes were similar to effect sizes when
either 25(OH)D levels or vitamin B12 levels were in the optimal range alone. Among those who were
none/slight/moderate anxious or depressed at baseline, there was no effect of the program when
participants had low vitamin B12 (<450 pmol/L) and 25(OH)D levels (<100 nmol/L) with small but
significant ES in those with high vitamin B12 and 25(OH)D that ranged from 0.22 to 0.29. Effect sizes
were similar but much larger in those who were in the severe/extreme group, with effect sizes that
ranged from 1.95 to 2.33 in the high vitamin B12 and 25(OH)D groups (Table 7). Per protocol analyses
revealed similar results to ITT (data available upon request).





(None/Slight/Moderate) (n = 15,194)
Baseline One Year Baseline One Year
Age (years) 47.2 ± 16 — 54.6 ± 16 —
BMI 27.6 ± 6.6 27.7 ± 2.9 27.5 ± 5.6 27.6 ± 3.0
Serum 25(OH)D (nmol/L) 71 ± 28 111 ± 16 a 76 ± 28 112 ± 19 a
Serum Vitamin B12 (pmol/L) 395 ± 360 1089 ± 420 a 383 ± 297 1090 ± 832 a
AA:EPA 18.9 ± 7.8 8.9 ± 5.0 b,c 15.4 ± 7.7 8.9 ± 4.6 b
TSL Depression 7.6 ± 2.4 3.7 ± 1.8 b,c 3.4 ± 2.4 2.9 ± 1.2 b
TSL Anxiety 7.9 ± 2.3 3.9 ± 1.8 b,c 3.7 ± 2.4 3.2 ± 1.2 b
TSL Mental Health Score 7.2 ± 1.9 3.6 ± 1.6 b,c 3.4 ± 2.0 2.9 ± 1.0 b
a Indicates significant difference from baseline within group, paired-t; b Indicates significant difference from baseline
within group, WSRT; c Indicates a significant difference between groups (Depressed/Anxious vs. Everyone Else),
Mann–Whitney U.
The effect of the nutrients on mental health outcomes were assessed with a nested case control
analysis. We selected 107 participants who were severely/extremely depressed/anxious (based
on EQ-5D) but did not take any psychiatric medication (cases), and compared them with 214
severely/extremely depressed/anxious participants, matched based on age, sex and BMI, who took
related psychiatric medication (controls). Following one year in program, nutrient levels significantly
increased in both the case and control groups. Serum 25(OH)D levels were higher in participants who
were not taking psychiatric medications in comparison with those taking medications at both baseline
and follow-up. There was no significant difference between depressed/anxious participants taking
vitamins and those taking both vitamins and medications (Table 8).
We additionally compared EQ-5D score improvements between depressed/anxious participants
taking no medication (cases) and those taking medication (controls). Again, we did not find any
significant difference between case and control groups (Table S3). In both groups, more than 90%
showed improvement in their mental status and the rest remained unchanged, regardless of their
related psychiatric medication status. No participants reported a worsened mental status.
We further investigated the effects of nutrient status on mental health outcomes through logistic
regression analyses. Participants taking anxiety- and/or depression-related medications were excluded
from the regression analysis (n = 700). Improvements in serum 25(OH)D concentration, such that
participants went from having suboptimal levels to optimal levels (≥100 nmol/L for 25(OH)D),
were found to be associated with improvements in anxiety, depression and MHS (Table 9). In addition,
physical activity significantly influenced anxiety and depression scores with moderate and strenuous
physical activity related to larger improvements to MHS. Age also influenced anxiety, depression and
MHS with younger participants showing larger improvements. Current tobacco use and inflammation
negatively affected mental health status.
Nutrients 2018, 10, 152 9 of 17
Table 7. Magnitude of Effect of Nutritional Status on Targeted Symptoms List (TSL) Depression and Anxiety at one-year follow-up in Severely/Extremely
Anxious/Depressed.
Effect Size Between Baseline and One-Year (95% CI)












Depression 0.59 [−0.01–1.20] 1.95 [1.80–2.09] 0.80 [0.37–1.24] 2.01 [1.86–2.16] 0.61 [−0.13–1.34] 2.05 [1.90–2.20]
Anxiety 0.60 [−0.01–1.20] 2.04 [1.89–2.19] 0.65 [0.22–1.07] 2.13 [1.98–2.28] 0.66 [−0.08–1.39] 2.18 [2.03–2.33]
Mental score 0.57 [−0.05–1.18] 2.20 [2.05–2.35] 0.78 [0.35–1.22] 2.28 [2.12–2.44] 0.54 [−0.19–1.27] 2.33 [2.17–2.49]
N 24 539 47 516 15 510
None/Slightly/Moderately Anxious/Depressed
Depression 0.06 [−0.04–0.16] 0.22 [0.19–0.25] 0.07 [−0.01–0.16] 0.23 [0.20–0.25] 0.04 [−0.09–0.17] 0.23 [0.20–0.26]
Anxiety 0.07 [−0.03–0.18] 0.23 [0.20–0.25] 0.11 [0.03–0.19] 0.23 [0.20–0.26] 0.05 [−0.08–0.18] 0.23 [0.21–0.26]
Mental score 0.10 [−0.01–0.20] 0.28 [0.26–0.31] 0.12 [0.04–0.21] 0.29 [0.26–0.32] 0.07 [−0.06–0.20] 0.29 [0.26–0.32]
N 730 10,303 1067 9966 452 9688
Cohen’s d (with confidence intervals) was used as a measure of effect sizes: 0.2 is small, 0.5 is medium, and 0.8 is large.
Table 8. Comparison of biomarkers of nutrition and mental health scores between case and control groups.
Parameter
Depressed/Anxious (Severe/Extreme)
on No Medications (Cases, n = 107)
Depressed/Anxious on Medications
(Controls, n = 214) Changes from Baseline p Value of Changes
Baseline One Year Baseline One Year Cases Controls
Age (years) 47.2 ± 15 — 47.1 ± 15 — — —
BMI 27.8 ± 6.5 27.3 ± 3.5 27.9 ± 6.0 27.8 ± 2.7 −0.54 ± 5.4 −0.10 ± 5.5 0.20
Serum 25(OH)D (nmol/L) 95 ± 49 130 ± 51 a 72 ± 20 106 ± 37 a 34 ± 45 34 ± 45 0.81
Serum Vitamin B12 (pmol/L) 441 ± 373 1061 ± 263 a 379 ± 399 1080 ± 393 a 619 ± 433 701 ± 548 0.06
AA:EPA 18.4 ± 6.2 8.9 ± 5.4 b 18.7 ± 8.5 10.5 ± 2.7 b −9.5 ± 6.2 −8.2 ± 6.8 0.76
TSL Depression 7.6 ± 2.5 3.6 ± 1.7 b,c 8.2 ± 1.9 3.9 ± 2.1 b −4.0 ± 2.7 −4.4 ± 2.6 0.36
TSL Anxiety 8.2 ± 2.0 4.0 ± 1.8 b,c 8.0 ± 2.2 4.1 ± 1.9 b −4.1 ± 2.6 −3.9 ± 2.7 0.66
TSL Mental Health 7.4 ± 1.9 3.6 ± 1.5 b,c 7.5 ± 1.7 3.8 ± 1.8 b −3.8 ± 2.2 −3.7 ± 2.3 0.96
a Indicates significant difference from baseline within group, paired-t; b Indicates significant difference from baseline within group, WSRT; c Indicates a significant difference between
groups (Depressed/Anxious and no meds vs. Depressed/Anxious on meds), Mann–Whitney U.
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Table 9. Binary Logistic Regression of influencing factors on Targeted Symptoms List (TSL) mental parameters over one year.
TSL Parameter Improvement Factor Exp (B) p Value 95% CI
Anxiety (R2 = 0.05, p < 0.001)
Age 0.99 0.90 0.977–1.021
Gender (Male) 0.91 0.75 0.526–1.597
Serum vitamin B12 (BL ≥ 450 pmol/L and FL ≥ 450 pmol/L) Reference
Serum vitamin B12 (BL < 450 and FL ≥ 450 pmol/L) 0.83 0.54 0.476–1.475
Serum 25(OH)D (BL ≥ 100 and FL ≥ 100 nmol/L) Reference 0.25
Serum 25(OH)D (BL < 75 and FL ≥ 100) 1.71 0.10 0.950–3.455
Serum 25(OH)D (BL 75–100 and FL ≥ 100) 1.03 0.92 0.564–1.872
BMI, kg/m2 0.98 0.70 0.522–1.546
Tobacco use (Never) Reference 0.53
Tobacco use (Quit smoking) 0.89 0.70 0.522–1.546
Tobacco use (current smoker) 0.51 0.26 0.156–1.668
Alcohol use (Never) Reference 0.61
Alcohol use (Light drinker) 0.73 0.32 0.392–1.369
Alcohol use (Heavy drinker) 0.63 0.62 0.096–4.120
Physical activity (No) Reference 0.74
Physical activity (Mild) 1.49 0.28 0.710–3.155
Physical activity (Moderate) 1.31 0.51 0.577–2.989
Physical activity (Strenuous) 1.16 0.79 0.386–3.486
Inflammation (CRP ≥ 10 mg/L) 0.25 0.18 0.032–1.936
AA:EPA 0.98 0.30 0.951–1.015
Depression (R2 = 0.1, p < 0.001)
Age 0.98 0.22 0.961–1.009
Gender (Male) 0.88 0.66 0.490–1.581
Serum vitamin B12 (BL ≥ 450 pmol/L and FL ≥ 450 pmol/L) Reference
Serum vitamin B12 (BL < 450 and FL ≥ 450 pmol/L) 0.77 0.41 0.428–1.418
Serum 25(OH)D (BL ≥ 100 and FL ≥ 100 nmol/L) Reference 0.15
Serum 25(OH)D (BL < 75 and FL ≥ 100) * 1.96 0.05 1.002–4.106
Serum 25(OH)D (BL 75–100 and FL ≥ 100) 1.57 0.16 0.836–2.955
BMI, kg/m2 0.98 0.65 0.940–1.040
Tobacco use (Never) Reference 0.59
Tobacco use (Quit smoking) 1.17 0.59 0.652–2.112
Tobacco use (current smoker) 0.65 0.46 0.203–2.064
Alcohol use (Never) Reference 0.42
Alcohol use (Light drinker) 1.49 0.20 0.808–2.755
Alcohol use (Heavy drinker) 1.04 0.96 0.169–6.474
Physical activity (No) Reference 0.47
Physical activity (Mild) 1.86 0.11 0.857–4.039
Physical activity (Moderate) 1.63 0.26 0.695–3.823
Physical activity (Strenuous) 1.80 0.34 0.535–6.060
Inflammation (CRP ≥ 10 mg/L) 0.37 0.13 0.102–1.349
AA:EPA 0.99 0.74 0.961–1.029
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Table 9. Cont.
TSL Parameter Improvement Factor Exp (B) p Value 95% CI
Mental score (R2 = 0.1, p < 0.001)
Age 0.98 0.11 0.957–1.005
Gender (Male) 0.83 0.55 0.472–1.493
Serum vitamin B12 (BL ≥ 450 pmol/L and FL ≥ 450 pmol/L) Reference
Serum vitamin B12 (BL < 450 and FL ≥ 450 pmol/L) 0.84 0.58 0.474–1.516
Serum 25(OH)D (BL ≥ 100 and FL ≥ 100 nmol/L) Reference 0.29
Serum 25(OH)D (BL < 75 and FL ≥ 100) 1.76 0.10 0.960–3.595
Serum 25(OH)D (BL 75–100 and FL ≥ 100) 1.18 0.59 0.639–2.192
BMI, kg/m2 1.02 0.55 0.965–1.068
Tobacco use (Never) Reference 0.67
Tobacco use (Quit smoking) 1.03 0.91 0.586–1.811
Tobacco use (current smoker) 0.59 0.39 0.170–2.023
Alcohol use (Never) Reference 0.75
Alcohol use (Light drinker) 1.11 0.73 0.602–2.053
Alcohol use (Heavy drinker) 0.59 0.58 0.086–4.01
Physical activity (No) Reference 0.05
Physical activity (Mild) * 2.46 0.02 1.155–5.23
Physical activity (Moderate) * 2.26 0.05 1.002–5.27
Physical activity (Strenuous) * 4.99 0.01 1.317–18.96
Inflammation (CRP ≥ 10 mg/L) 0.73 0.59 0.227–2.349
AA:EPA * 0.98 0.03 0.956–0.998
* Significant predictors, BL = baseline, FL = Follow-up, BMI = Body Mass Index, Fruit, vegetable, and fish consumption were removed from model because of almost zero effect size and
for simplicity.
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4. Discussion
This study found that participants in an intervention program aimed at chronic disease prevention
that provides nutritional supplements showed significant improvement in self-reported depression
and anxiety over the course of one year. This was a large database with over 16,000 participants who
had completed the questionnaires, EQ-5D and the TSL, at program entry. At baseline, over half of
these participants reported some level of depression and anxiety, suggesting that a large number of
people suffer from subclinical mood disturbances. Severe and extreme depression and anxiety was
reported in 5.2% of the population which is consistent with a prevalence of depression of 5.4% in
Canadians [3,51].
Overall, significant improvements were found for depression and anxiety after one year in the
program. This is notable given that the majority of the population reported only mild levels of
depression and anxiety at baseline (effect size 0.21 and 0.22, respectively). More notable, over 90% of
those who reported severe or extreme depression or anxiety at program entry reported improvement
at one year (effect size 1.85 and 1.94, respectively).
Vitamin D deficiency was highly prevalent among severely/extremely depressed/anxious
participants and achieving physiological serum 25(OH)D concentrations (above 100 nmol/L) was
found to have a significant influence on mental health improvements in the context of the rest of the
program, particularly for depression.
All participants received multiple nutritional supplements including the Vital 2 Platinum
multivitamin/mineral supplement, vitamin B12, omega 3 and vitamin D3 supplementation. However,
achieving serum 25(OH)D concentrations above 100 nmol/L and vitamin B12 levels above 450 pmol/L,
safely [37], positively influenced depression and anxiety outcomes. The results suggest that nutrient
intervention impacts depression to a greater extent than anxiety, but both were positively influenced.
Others have found that vitamin D3 supplementation has led to improvements in depression [40,52–57],
yet others have not [58–60]. A meta-analysis demonstrated the importance of dose, frequency
and achieving measurable increases in 25(OH)D concentrations in being able to detect favourable
depression outcomes [61]. Our results support those of Kaplan et al. who demonstrated that vitamin
B complex and multivitamin/mineral formulas have resulted in greater reductions in stress and
anxiety compared with vitamin D3 supplementation alone [29]. A systematic review of the evidence
demonstrates a significant number of trials that overall provide sufficient support for the use of
B vitamins in the treatment of stress and anxiety in the general population, the benefit of which may
be augmented with a broad array of minerals [13]. It is hypothesized that assuring all of the necessary
cofactors for all metabolic processes improves mental resilience to stress and thus improves one’s ability
to cope. Given that the clinical intervention involves vitamin D3 in combination with MVM and vitamin
B12, among other nutrients, the authors posit that, where vitamin D3 was found to be a significant
predictor of improvements, the magnitude was dependent upon an optimal background of other
nutrients. While optimal vitamin D levels are necessary for nearly every cell, it is but one component
needed for proper functioning of all metabolic systems of the body. Moreover, the absorption of certain
nutrients such as vitamin B12 may be affected by different disease conditions (pernicious anemia,
and H. pylori infection) or medications such as acid blockers or psychiatric medications that may inhibit
vitamin D absorption. These may explain the discrepant results from other studies involving vitamin
D3 or vitamin B12 as a stand-alone treatment.
More strenuous physical activity was found to be associated with improved mental health status.
There is growing evidence that physical activity has protective effects not only on physical health but
also on mental health, particularly depression and anxiety. Engaging in regular physical activity led to
fewer depression and anxiety symptoms than did being inactive, which may also be related to vitamin
D synthesis via sun exposure [62–64]. The anti-inflammatory effect of omega 3 have been successfully
linked to preventing or treating depression [65,66], and B vitamins appears to treat anxiety, depression
and stress [13,67], although we found the predominant effect for vitamin D.
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The strengths of the present study include the large community-based population. The authors
are unaware of any other study of a clinical intervention with as many participants as included here.
Further, the population was not limited to clinically depressed individuals and found beneficial effects
for the population in general.
The main limitations of this study are the lack of details of the other treatment options participants
engaged in outside of the program (e.g., mediation or counselling). The data analysed here were
collected as part of a clinical intervention, a real life program not specifically designed for research;
hence, we were not able to ensure compliance and a high drop-out rate was expected. We used
intent-to-treat analysis and found results compatible with the results of per protocol analysis.
Following program entry, participants were provided with a standard package of multiple nutrients
(multivitamin/mineral, vitamin D3, omega-3 fatty acids, vitamin B12, vitamin C and probiotics).
In addition, nearly half of the participants were recommended additional supplements based upon
individual requirements—for example, magnesium may have been recommended to an individual
experiencing leg cramps or constipation. Vitamin D3 supplementation in the program was targeted at
achieving a serum 25(OH)D concentration above 100 nmol/L rather than a specific dose of vitamin
D3, but the rest of the supplements were provided at the standard dose. Because the data are from a
voluntary health and wellness program, albeit a clinical intervention, there is likely to be a selection
bias. Further, due to the nature of the study we were not able to measure compliance to the program,
but the results do reflect real-life response. Small but significant differences were detected in a
baseline comparison between those who persisted in the program and those who did not; there
was a significantly higher proportion (6.0%) of severe/extreme depressed/anxious at baseline who
dropped-out of the program in comparison with those who persisted to one year (2.7%). In addition,
the measurement of depression and anxiety was through a standardized questionnaire rather than a
clinical assessment. The results presented here represent a real-life scenario rather than a clinical study.
Currently, the front line form of treatment for depression is psychopharmaceutical, but there
is growing interest in exploring the role of nutrients. Nutritional status plays an important role in
mental health, and poor nutrition may contribute to the pathogenesis of mental illness. Nutritional
deficiencies could have an influence on brain structure and function, including mood, anxiety and
depression. We found depression and anxiety were commonly reported in the participants of this
clinical intervention. This analysis showed that improvements in depression and anxiety were
associated with achieving serum 25(OH)D concentrations of at least 100 nmol/L. A nutrient-based
program aimed at achieving optimal nutrition may provide a safe, simple and economical means of
supporting mental health.
5. Conclusions
Overall, this analysis of a large database sample (n = 16,020), in which over half of the population
reported some level of depression and anxiety, confirms the high rate of people in the general
population who suffer from mood and anxiety problems. The current study suggests that general
mood may benefit from improved nutritional status. Nutritional status plays an important role in
mental health, and poor nutrition may contribute to the pathogenesis of mental illness. Broad spectrum
supplements with a focus on optimizing vitamin D status may provide a new paradigm for treatment
and prevention of mental illness.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/2/152/s1,
Table S1: Comparison of Multivitamin/mineral formulations: Vital 2 Platinum vs. EMPowerplus Table S2:
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Comparison of change in reported level of depression and anxiety at one year between case and control groups.
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